Congenital Bile Acid Synthesis Defect 2

Congenital bile acid synthesis defect 2 is a very rare inherited liver disease. It happens when the body cannot make normal bile acids in the right way. Bile acids are natural chemicals made in the liver. They help bile flow, help the body digest fat, and help the body absorb vitamins A, D, E, and K. In this disease, abnormal bile acid chemicals build up and can hurt the liver. The problem usually starts in babies or young infants, and it can become serious if it is not found early. [1]

Congenital bile acid synthesis defect 2, also called AKR1D1 deficiency or delta-4-3-oxosteroid 5-beta-reductase deficiency, is a very rare inherited liver disease. In this condition, the liver cannot make normal primary bile acids well. Because bile acids are needed for bile flow, fat digestion, and absorption of vitamins A, D, E, and K, patients can develop jaundice, cholestasis, poor growth, bleeding, weak bones, and liver damage. This disease often starts in infancy and can become severe very fast if it is not recognized early.

This disease is also called a bile acid synthesis disorder because the main problem is in the step-by-step making of bile acids from cholesterol. The changed gene is called AKR1D1. This gene gives instructions for an enzyme that works in an early step of bile acid production. When the enzyme does not work well, normal bile acids become low, and unusual bile acid intermediates rise. These unusual chemicals can damage liver cells and reduce bile flow. [2]

This condition is inherited in an autosomal recessive way. That means a child usually gets one changed copy of the gene from each parent. The parents are often healthy carriers because one working copy is usually enough for them. A baby becomes sick when both copies have harmful changes. [3]

Other names

Other names used for this disease include CBAS2, congenital bile acid synthesis defect type 2, bile acid synthesis defect congenital 2, BASD type 2, AKR1D1 deficiency, Δ4-3-oxosteroid 5β-reductase deficiency, and cholestasis with delta(4)-3-oxosteroid 5-beta-reductase deficiency. These names all point to the same disorder. [4]

In the bigger disease group, doctors often list congenital bile acid synthesis defects by type. The main named types include type 1, type 2, type 3, and type 4. This answer is only about type 2, which is the AKR1D1 form. [5]

Causes

There is really one main root cause of CBAS2: disease-causing changes in both copies of the AKR1D1 gene. Still, to make this easy to understand, here are 20 cause-related points doctors use to explain how the disease starts or becomes severe. Orphanet

1. AKR1D1 gene mutation means the body instruction for the enzyme is changed. 2) Two altered gene copies are usually needed for the disease to happen. 3) Autosomal recessive inheritance explains why healthy parents can have an affected child. 4) Too little 5β-reductase enzyme means the liver cannot do one normal chemical step. 5) Poor bile acid production lowers the amount of normal primary bile acids. NIH GARD

2. Weak bile flow happens because normal bile acids help drive bile movement. 7) Build-up of abnormal bile acid intermediates can harm liver cells. 8) Fat malabsorption starts because bile acids are needed to absorb dietary fat. 9) Poor absorption of vitamins A, D, E, and K follows because these vitamins need fat for absorption. 10) Vitamin K deficiency can lead to easy bleeding or clotting problems. NCBI review

3. Early infant cholestasis means bile gets stuck in the liver from the beginning. 12) Liver cell injury can grow over time if treatment is delayed. 13) Inflammation in the liver may develop from long-term toxic build-up. 14) Fibrosis, which means liver scarring, can appear after ongoing injury. 15) Cirrhosis, which means severe permanent scarring, can develop in untreated cases. NIH GARD

4. Liver failure risk rises when cirrhosis becomes advanced. 17) Delayed diagnosis acts like a cause of worse disease because treatment starts late. 18) No bile acid replacement treatment allows the abnormal pathway to continue. 19) Family history of the same gene defect increases the chance in brothers or sisters. 20) Carrier parents in the same family line raise recurrence risk in future pregnancies. These last points do not create the mutation, but they explain why the disease appears or worsens in real life. Case series

5. Each parent may be an unaffected carrier. Carriers can pass the changed gene to the baby. [10]

6. A missense variant can cause the disease. This means one DNA change makes the enzyme protein built in the wrong way. [11]

7. A splice-site variant can cause the disease. This type of change can make the cell read the gene message incorrectly. [12]

8. A nonsense variant can cause the disease by making the protein stop too early. Then the enzyme may be very short and weak. [13]

9. A small deletion in the gene can cause loss of important genetic letters, which can damage enzyme function. [14]

10. A small insertion can also disturb the gene message and make a faulty enzyme. [15]

11. Some variants make the enzyme unstable, so it breaks down too fast inside the liver cell. [16]

12. Some variants let the enzyme form, but the enzyme has very low activity. It is present, but it does not work enough. [17]

13. Because the blocked step is early in bile acid production, the body makes too little cholic acid and too little chenodeoxycholic acid, which are normal primary bile acids. [18]

14. At the same time, abnormal bile acid intermediates build up. These unusual chemicals are harmful to the liver. [19]

15. The liver then has trouble making normal bile flow, which leads to cholestasis, meaning bile does not move out well. [20]

16. Poor bile flow causes poor absorption of fat, so the body cannot use food fat normally. [21]

17. Poor fat absorption also causes low uptake of vitamins A, D, E, and K, which can add more health problems. [22]

18. In some families, related parents increase the chance that a child receives the same rare changed gene from both sides. This does not create the mutation, but it raises the risk of the recessive disease appearing. [23]

19. Different AKR1D1 variants can cause different severity. Some babies become very sick early, while some rare people have milder disease. [24]

20. The disease can be missed because it may look like other infant liver problems, but the true cause is still the same AKR1D1 enzyme defect. [25]

21. So, in very simple words, the final cause is this: a baby inherits two harmful AKR1D1 gene changes, the enzyme step fails, normal bile acids fall, toxic bile chemicals rise, and the liver becomes sick. [26]

Symptoms

Symptoms can be different from child to child, but doctors often see the disease as a form of cholestatic liver disease. Cholestasis means bile is not moving out of the liver the right way. Some babies look sick very early, while some children are diagnosed later because the signs are unclear at first. GARD/NIH

1. Jaundice means yellow skin or yellow eyes from bilirubin build-up. 2) Dark urine happens because extra bilirubin leaves through urine. 3) Pale or light stools can happen when bile does not reach the gut well. 4) Hepatomegaly means an enlarged liver. 5) Abdominal swelling can happen from enlarged liver, gas, fluid, or poor nutrition. Review

2. Poor feeding means the baby does not eat well. 7) Failure to thrive means poor weight gain and slow growth. 8) Diarrhea or loose stools may happen when fat is not absorbed well. 9) Steatorrhea means greasy, bulky, bad-smelling stools because fat stays in stool. 10) Vomiting can happen in some babies with liver and feeding problems. NCBI review

3. Easy bruising or bleeding can happen from vitamin K deficiency. 12) Bone weakness or rickets may happen from low vitamin D. 13) Muscle weakness or nerve problems can appear when vitamin E stays low for a long time. 14) Poor vision in low light may happen with vitamin A deficiency. 15) Tiredness or weakness can come from chronic illness and poor nutrition. NCBI Bookshelf

4. Enlarged belly veins or fluid in the belly can appear in advanced liver disease. 17) Itching may happen in cholestasis, but in some bile acid synthesis defects itching can be mild or even absent. 18) Liver scarring signs may slowly develop. 19) Delayed growth can continue over months if untreated. 20) Serious liver failure can happen in severe untreated cases. Not every child has all 20 signs. Mechanisms review

Diagnostic tests

Doctors diagnose CBAS2 by putting together the story, physical signs, lab results, and very special bile acid tests. One important clue is cholestasis with normal or low gamma-glutamyl transferase (GGT) and often normal or low total bile acids, which is unusual for many other liver diseases. PubMed case report

Physical exam

1. General inspection means the doctor looks for jaundice, poor growth, thin body, swelling, and signs of vitamin deficiency. 2) Skin and eye exam checks yellow color, bruises, and sometimes scratch marks. 3) Abdominal palpation means the doctor gently feels the belly to check for a large liver or spleen. 4) Growth measurement checks weight, length, and head size over time. These are simple but very important first steps. NCBI Bookshelf

Manual test

1. There is no special manual bedside test that by itself proves CBAS2. In simple words, doctors cannot confirm this disease just by using their hands or one quick clinic maneuver. Manual examination helps find liver enlargement, belly swelling, signs of dehydration, poor muscle bulk, or rickets, but the final diagnosis needs laboratory and genetic proof. Review

Lab and pathological tests

5. Liver function tests measure bilirubin, ALT, AST, alkaline phosphatase, and GGT. In CBAS2, bilirubin and liver enzymes may be high, but GGT can stay normal or low. 6) Coagulation tests such as PT or INR check how well blood clots, and they may be abnormal because of vitamin K deficiency or liver failure. 7) Serum bile acid testing may show unexpectedly normal or low levels for a child with cholestasis. 8) Fat-soluble vitamin levels help show deficiency of vitamins A, D, E, and K. PubMed case report

6. Urine bile acid mass spectrometry is one of the most important tests. This test looks for unusual bile acid patterns in urine. In CBAS2, it can show abnormal 3-oxo-Δ4 bile acids, which strongly points to the enzyme block. 10) Blood or plasma bile acid profiling may also help show the abnormal pattern. These tests are highly useful because they look at the exact chemicals the body is making. Cholic acid review

7. Genetic testing of AKR1D1 confirms the diagnosis by finding disease-causing variants in the gene. This may be done by single-gene testing, a cholestasis panel, or wider sequencing. 12) Carrier testing in family members may be offered after a child is diagnosed. 13) Prenatal or future pregnancy testing may be possible in some families when the exact mutation is known. Case series

8. Liver biopsy is a pathological test where a tiny piece of liver is examined under a microscope. It may show cholestasis, giant cell change, liver cell injury, inflammation, fibrosis, or cirrhosis. Biopsy can support the diagnosis and help measure liver damage, but it is not as specific as bile acid analysis plus gene testing. OMIM/NCBI summary

Electrodiagnostic tests

15. Electrodiagnostic tests are not routine for CBAS2. Tests such as nerve conduction studies or EMG are usually not used to make the diagnosis. In rare long-standing cases with severe vitamin deficiency, a doctor may order nerve-related testing to check complications, but that is not the standard way to prove this disease. NCBI review

Imaging tests

16. Abdominal ultrasound is commonly used first. It can show liver size, liver texture, spleen size, and whether there is another cause such as blocked bile ducts. 17) Doppler ultrasound can check blood flow in liver vessels. 18) Elastography may help estimate liver stiffness, which gives a clue about fibrosis. 19) MRI or MRCP may be used in selected cases to look more closely at the liver and bile ducts and to rule out other disorders. 20) Imaging overall is supportive, not specific. It helps exclude other diseases and measure damage, but it does not replace urine bile acid testing or AKR1D1 genetic testing. Neonatal cholestasis review

Main non-drug treatments and supportive therapies

1) Early diagnosis and specialist follow-up. The best non-drug step is fast diagnosis by a pediatric liver specialist or metabolic specialist. Early treatment can stop ongoing liver injury before cirrhosis develops. Follow-up usually includes clinical review, growth checks, liver blood tests, clotting tests, bile acid studies, and vitamin monitoring. This is important because the disease can worsen quickly in babies and young children.

2) Nutrition assessment. A dietitian helps prevent malnutrition, which is common because fat absorption is poor when bile acids are low. Nutrition care focuses on enough calories, enough protein, growth monitoring, and replacement of missing vitamins and trace nutrients. Good nutrition does not correct the gene defect, but it lowers the risk of growth failure and weakness.

3) Medium-chain triglyceride support. Medium-chain triglycerides, often called MCTs, are a special form of fat that can be absorbed more easily than long-chain fats. They are often used in cholestatic liver disease to improve calorie intake and support growth. Evidence is stronger for cholestatic liver disease in general than for AKR1D1 deficiency alone, so this is supportive care, not disease-correcting care.

4) Growth monitoring. Regular weight, length or height, head growth in infants, and body mass tracking help doctors see whether treatment is working. Poor growth may be the first sign that fat and vitamins are still not being absorbed well. Growth charts are therefore a treatment tool, not only a record.

5) Monitoring for bleeding. Low vitamin K absorption can cause bruising or dangerous bleeding. Families are often taught to seek urgent help for nosebleeds, black stool, vomiting blood, or unusual bruising. Careful monitoring is a very important non-drug safety step.

6) Bone health care. Poor vitamin D absorption can weaken bones and cause rickets or fractures. Bone care includes sunlight exposure as appropriate, age-appropriate movement, fall prevention, bone blood tests, and sometimes imaging when weakness or fractures are suspected.

7) Developmental support. Infants and children with chronic cholestatic illness may become weak, tired, or delayed because of malnutrition and vitamin deficiency. Physical therapy, feeding therapy, and developmental follow-up can help function and recovery, especially when treatment starts late.

8) Skin care for itching or jaundice-related irritation. Some cholestatic patients develop dry skin, irritation, or scratching. Gentle skincare, keeping nails short, hydration, and sleep support can improve comfort even though these steps do not fix the liver problem itself.

9) Vaccination and infection prevention. Children with liver disease need strong routine preventive care. In people with advanced liver dysfunction, infections can cause quick deterioration. Good hand hygiene, vaccination, and prompt review for fever are practical protective steps.

10) Genetic counseling. This disorder is inherited, so family counseling matters. It helps parents understand recurrence risk, sibling testing, and future pregnancy planning. This is especially useful because early recognition can greatly change outcome.

Drug treatments

Most important disease-specific drug: Cholic acid (CHOLBAM). Cholic acid is the key evidence-based treatment because it directly replaces a missing primary bile acid. The FDA label states it is indicated for bile acid synthesis disorders due to single-enzyme defects. The usual dose is 10 to 15 mg/kg/day by mouth, given once daily or in two divided doses. Its purpose is to restore the bile acid pool, improve bile flow, reduce toxic abnormal bile acid intermediates through feedback suppression, improve fat digestion, and improve absorption of fat-soluble vitamins. The FDA label says common adverse effects include diarrhea, reflux esophagitis, malaise, jaundice, nausea, abdominal pain, urinary tract infection, and peripheral neuropathy. Liver tests must be monitored closely, especially early in treatment.

Important note about other bile acids. Some case reports and small series describe chenodeoxycholic acid (CDCA) use in AKR1D1 deficiency, and some patients improved. However, reviews also report that pronounced AKR1D1 deficiency may worsen with CDCA alone in some patients, while cholic acid is the FDA-approved drug for single-enzyme bile acid synthesis disorders. Because of this, bile acid choice should be made only by a specialist with bile acid testing.

Ursodeoxycholic acid (ursodiol). Ursodiol is sometimes used before diagnosis or for cholestatic symptoms, but it is not the preferred disease-correcting long-term treatment for AKR1D1 deficiency. One review specifically says UDCA is not recommended for long-term management of this defect because primary bile acid replacement is the real mechanism-based treatment.

Vitamin K1 (phytonadione). This is a supportive drug, not a cure. It is used when vitamin K deficiency or coagulopathy is suspected or proven. Its purpose is to improve clotting factor activation and reduce bleeding risk. In cholestatic disease, vitamin K may be needed orally or by injection if absorption is poor. Injectable vitamin K can rarely cause severe hypersensitivity reactions, so it must be used carefully. Dose is individualized by age, lab results, and urgency.

Vitamin E, especially water-soluble tocophersolan or TPGS-based forms. Vitamin E deficiency is common in cholestatic disorders because fat absorption is poor. Water-soluble forms are important because they absorb better than standard fat-based products. Reviews report oral TPGS around 20 to 25 IU/kg/day can prevent or correct deficiency in pediatric cholestasis. Its purpose is to protect nerves, muscles, and cell membranes from oxidative damage.

Vitamin D or active vitamin D support. Vitamin D deficiency can occur because fat-soluble vitamin absorption is impaired. Supportive treatment may use cholecalciferol or, in selected cases, active forms such as calcitriol under specialist supervision. The goal is to improve calcium balance and bone mineralization. Calcitriol dosing must be individualized because too much can cause high calcium.

Vitamin A. Vitamin A may be needed when deficiency causes poor vision, dry eyes, poor growth, or immune problems. In cholestatic infants, higher-than-standard supplementation is often needed because absorption is poor, but exact dosing must be individualized and monitored to avoid toxicity. Its main function is support of vision, immunity, skin, and growth.

There are no evidence-based “immunity booster,” regenerative medicine, or stem-cell drugs that are approved specifically for congenital bile acid synthesis defect 2. At present, these approaches should not be presented as standard care. For this disease, the established medical strategy is still primary bile acid replacement, correction of vitamin deficiency, careful monitoring, and liver transplant when medical therapy fails or liver disease is too advanced.

Dietary and molecular supplements

The most useful supplement group is the fat-soluble vitamins A, D, E, and K because the disease causes poor absorption of these vitamins. They are given to restore normal body stores, lower bleeding risk, support bone growth, protect nerves, and improve eye and immune function. In cholestatic children, regular blood monitoring is needed because some vitamins stay low despite treatment, while others can become too high if replaced too aggressively.

Vitamin A supports vision, skin, immune defense, and growth. Vitamin D supports calcium absorption and bone strength. Vitamin E protects nerves and cell membranes from oxidative injury. Vitamin K supports normal blood clotting. These are not optional wellness products in this disease; they are part of core deficiency management.

MCT oil or MCT-enriched feeds are often used as nutritional supplements because they give calories that are absorbed more easily than many other fats. They help energy intake and growth, but they do not replace essential fatty acids, so the diet still needs balance. Very high MCT use without balance may create other nutrition problems.

Procedures and surgeries

Liver transplantation is the main major surgery for patients with advanced liver failure, decompensated cirrhosis, or failure of medical therapy. It is done because the liver is the organ that cannot make bile acids correctly, and a healthy transplanted liver can correct that metabolic problem. In severe untreated cases, transplant may be life-saving.

Liver biopsy is not a treatment by itself, but it is an important procedure. It may be done to assess fibrosis, cholestasis, or unclear liver disease. In this disorder, biopsy can help measure damage and exclude other causes of neonatal cholestasis.

Enteral feeding tube placement may be needed in babies or children with severe feeding difficulty, poor growth, or high-calorie needs. The reason is nutritional rescue, not disease correction. It can help deliver enough calories, protein, vitamins, and MCT-based formulas consistently.

Central venous access procedures are sometimes needed in very sick children who require prolonged hospital care, parenteral vitamin replacement, or intensive nutritional support. This is a supportive procedure for severe cases, not standard therapy for all patients.

Cholecystectomy is not routine for this disease, but the FDA cholic acid label reports symptomatic gallstones requiring cholecystectomy in a patient from the clinical experience. This means gallbladder surgery may be needed if a complication develops, not because it treats the underlying gene defect.

Prevention and when to see a doctor

This genetic disorder cannot be fully prevented after conception, but complications can often be prevented by early diagnosis, newborn cholestasis evaluation, family genetic counseling, specialist care, strict medicine adherence, vitamin monitoring, nutrition support, growth checks, bleeding surveillance, and early transplant referral when needed. These steps reduce the chance of irreversible liver injury and severe deficiency complications.

A patient should see a doctor urgently for yellow eyes or skin, dark urine, pale stool, poor feeding, poor weight gain, easy bruising, bleeding, swollen belly, severe tiredness, vomiting, fever, worsening jaundice, or confusion. Babies with cholestasis should be evaluated quickly because rare metabolic liver diseases can worsen fast. The FDA label for cholic acid also recommends specialist initiation and close lab monitoring.

What to eat and what to avoid

Eat enough calories, enough protein, balanced carbohydrate, and specialist-guided fat intake. Many patients benefit from MCT-containing foods or formulas, individualized vitamin supplementation, and regular meals that support growth. In infants, breast milk or formula planning should be guided by the treating team, especially if weight gain is poor.

Avoid self-prescribed herbal liver products, random “detox” supplements, alcohol in older patients, very unbalanced fat restriction, and stopping bile acid therapy without medical advice. Also avoid drug interactions that can reduce cholic acid absorption, such as bile acid binding resins close to dosing time, unless the specialist gives a timing plan.

Frequently asked questions

Is this disease curable? It is often treatable, and many patients improve a lot if therapy starts early. The gene change remains, but cholic acid can replace missing bile acids and reduce toxic metabolites. In advanced disease, transplant may be needed.

Is cholic acid the most important medicine? Yes. It is the main FDA-approved disease-specific medicine for single-enzyme bile acid synthesis disorders.

Can vitamins alone treat the disease? No. Vitamins treat consequences of poor absorption, but they do not correct the bile acid synthesis defect itself.

Why are vitamins A, D, E, and K so important? Because bile acids are needed to absorb them. Low levels can cause bleeding, weak bones, nerve problems, and vision issues.

Is ursodiol enough? Usually no. Reviews say long-term management should focus on primary bile acid replacement rather than UDCA alone.

Can this disease cause liver failure? Yes. Untreated disease can progress to cirrhosis and liver failure.

Can adults have it? Yes, but many cases start in infancy. Some newer reports show variable severity, yet classic disease usually presents early.

Is genetic testing useful? Yes. It confirms AKR1D1-related disease and helps family counseling.

Can pregnancy planning benefit from counseling? Yes. Because this is inherited, counseling can help families understand recurrence risk.

Are stem-cell or immune booster treatments standard? No. There is no established evidence-based standard use of such therapies for this disease.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: March 10, 2025.